Swedish pharmaceutical company Medivir AB (STO:MVIR) announced on Monday that it has entered into a clinical trial collaboration and supply agreement with Japan's Eisai Co Ltd (TYO:4523) to evaluate fostrox in combination with lenvatinib in a Phase 2b study for second-line advanced liver cancer.
The combination therapy has shown encouraging anti-tumour activity and a manageable safety profile in a previous Phase 1b/2a study, with a median time to progression of 10.9 months.
Fostrox, an oral, liver-targeted treatment, has the potential to become a significant therapeutic option for patients with advanced liver cancer.
The collaboration with Eisai will allow Medivir to accelerate the development of fostrox and address a significant unmet medical need.
Neogap Therapeutics partners with NorthX Biologics to enhance cancer cell therapy production
Medivir partners with Eisai to evaluate fostrox in liver cancer
OSE Immunotherapeutics' Lusvertikimab shows promise in ulcerative colitis
Cytoki Pharma doses first patient with CK-0045 in Phase two proof-of-concept trial
Amphix Bio receives USD1m SBIR Phase II grant from National Science Foundation
Bexion Pharmaceuticals reports release of first-in-human data from Phase 1 study of BXQ-350
Eisai completes rolling BLA submission for lecanemab-irmb to FDA
Boehringer Ingelheim discontinues development of NYP2 agonist